Efficacy of Oral Azithromycin versus Oral Doxycycline in Treating Moderate Acne Vulgaris and Their Effects on Patients' Quality of Life

Efficacy of Oral Azithromycin versus Oral Doxycycline in Treating Moderate Acne Vulgaris and Their Effects on Patients' Quality of Life | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Efficacy of Oral Azithromycin versus Oral Doxycycline in Treating Moderate Acne Vulgaris and Their Effects on Patients' Quality of Life Asma AL Shidhani, Youssef Elsawy Mohammed, Jumana Al Saraii, Asma AL Salmani, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8068584/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 27 Apr, 2026 Read the published version in Scientific Reports → Version 1 posted 18 You are reading this latest preprint version Abstract This study aimed to compare the efficacy of oral azithromycin with oral doxycycline in moderate acne vulgaris and to assess the corresponding changes in patient-reported quality-of-life. In this open label, randomised controlled trial conducted at a university student clinic, Muscat, Oman, 163 patients with moderate and severe acne vulgaris were assigned equally to receive either oral azithromycin or oral doxycycline. Treatments were administered over a three-month period with monthly clinical assessments. Acne severity was quantified using a validated acne severity scale, and quality of life was measured at baseline and at study end via a standardised questionnaire. Analyses were performed using univariate statistics. The cohort comprised 163 participants (mean age 20.2 ± 1.7 years; 67.3% female). Both groups experienced significant and comparable reductions in acne severity after three months. Parallel, statistically significant improvements were observed in quality-of-life scores across domains related to symptoms, emotional well-being, and social functioning. Oral azithromycin and doxycycline demonstrate equivalent efficacy in reducing moderate acne vulgaris and both confer substantial enhancements in patients’ quality of life. These findings support either antibiotic as an appropriate option for addressing both the dermatological and psychosocial burdens of moderate acne. The trial was registered with the Australia New Zealand Clinical Trial Registry (ACTRN12619000073101; Date: 18th of January 2019). Acne Vulgaris doxycycline Azithromycin Oman QoL Figures Figure 1 Introduction Acne vulgaris is an inflammatory disorder of the pilosebaceous unit, in which proliferation of Cutibacterium acnes is precipitated by increased androgen activity during adolescence. 1 Clinically, it manifests as a mixture of comedones, papules, pustules and nodules on the face, upper arms, trunk, and back, with global prevalence estimates among adolescents ranging from approximately 35% to over 90%. 2 When moderate to severe inflammatory lesions fail to response adequately to topical therapies, systemic antibiotics such as doxycycline and azithromycin are indicated. 3 Doxycycline, a tetracycline derivative, has long been considered first-line but is frequently associated with photosensitivity and gastrointestinal upset. 4 In contrast, azithromycin, a macrolide, offers a more favorable side-effect profile and is deemed safe for use during pregnancy and lactation. 4 , 5 Comparative studies have yielded mixed outcomes: some report superior lesion-count reductions with doxycycline, while others demonstrate equivalent efficacy for azithromycin. 5 , 6 Although often dismissed as a transient adolescent condition, acne vulgaris imposes a substantial psychosocial burden that extends well beyond cutaneous involvement. 7 Affected individuals frequently experience diminished quality of life, impaired self-esteem and increased symptoms of anxiety and depression. 8 In adults, acne has also been linked to higher unemployment rates and, in severe cases, elevated risk of suicidal ideation. 9 Multiple investigations confirm that stigmatization and peer teasing further exacerbate psychosocial distress in acne patients. 10 , 11 Epidemiological data consistently show greater impairment among females, 8 with one study at King Abdulaziz University Hospital in Jeddah identifying the role-social domain as most compromised among female students. 12 Research at Sultan Qaboos University in Oman similarly found the role-emotional domain to be the most affected across both genders. 13 Evaluating both clinical efficacy and psychosocial outcomes is essential for comprehensive acne management. This study thus compares oral doxycycline and azithromycin in moderate acne vulgaris, examining patterns of dropout and loss of follow-up, and assesses changes in health-related quality of life before and after treatment. Methods This phase IV, open-label, randomised controlled trial was conducted at the Sultan Qaboos University hospital student clinic, Muscat, Oman, from July 2023 to March 2024. Based on power calculations to detect an absolute difference in response rates of 25–50% with 90% power at an alpha of 0.05, a sample size of 170 patients (85 per arm) was required. Students aged 17–25 years with newly diagnosed moderate acne vulgaris (per the Acne Severity Scale) were screened. Exclusion criteria included systemic antibiotic use within the preceding months, pregnancy, current topical anti-acne or systemic steroid therapy, oral contraceptive use, active liver disease, or known allergy to azithromycin or doxycycline. Eligibility was confirmed by detailed history and complete physical examination, and written informed consent was obtained. Participants were stratified by gender and randomised—using a computer-generated sequence managed by an independent physician—to one of two treatment arms. Patients in the azithromycin arm received 500 mg once weekly (on Fridays) for the following 12 weeks, while those in the doxycycline arm were administered 100 mg once daily after meals throughout the 12-week treatment period. Monthly follow-up visits with an independent assessor documented acne severity and adverse events. Lesion clearance was categorised by percentage reduction—excellent (100%), good (80–90%), moderate (50–79%), mild (30–49%), and no response (< 30%)—and side effects reported using the hospital adverse drug reaction (ADR) form. The primary response to treatment was assessed by using the difference in acne severity scale before treatment and after 3 months of treatment. All participants completed the validated Arabic acne-specific quality of life questionnaire (Acne-QoL) before treatment initiation and at week 12, assessing four domains: self-perception, role-social, role-emotional, and acne symptoms. 14 A total of 18 questions were distributed between these four domains. Permission to use the Acne-QoL was also obtained. Ethical approval was granted by the Medical Research Ethics Committee of the College of Medicine & Health Sciences (MREC#1914; 2/6/2019) and the trial was registered with the Australia New Zealand Clinical Trial Registry (ACTRN12619000073101; 18/1/2019). Written informed consent was obtained from each participant and participants below 17 years a parental informed consent was taken. All methods were followed according to relevant guidelines and regulations. Data were analysed using the Statistical Package for the Social Science (SPSS), Version 23 software (IBM Corp, Armonk, New York, USA). Quantitative variables are presented as mean ± standard deviation. Between-group differences were assessed by independent t-test. paired t-test. and one-way ANOVA as appropriate, with P < 0.05 denoting statistical significance. Results A total of 163 participants were randomised, with 83 (50.9%) assigned to the azithromycin group and 80 (49.1%) to the doxycycline group. Overall, 68.7% (n = 112) were female; the mean age was 19.75 ± 1.73 years (Table 1 ). Table 1 Age and gender distribution of study participants by treatment group (N = 163). Characteristic Azithromycin Group Doxycycline Group P -Value Age (mean ± SD) 19.95 ± 1.710 19.54 ± 1.743 0.550 Gender Male 26% 25% 0.984 Female 57% 55% SD = standard deviation Baseline acne severity was comparable between groups (68 versus 64 moderates, 14 versus 16 severe, and 1 versus 0 very severe in the azithromycin versus doxycycline groups; P = 0.911; Table 2 ). After 12 weeks, both regimens produced marked improvement: in the azithromycin group, 35 participants achieved clear skin, 19 had mild and 7 had moderate residual lesions, with none remaining in severe or very severe categories; in the doxycycline group, 37 achieved clear skin, 16 mild and 3 moderate severity, with one patient each in the severe and very severe categories ( P = 0.704). The mean acne severity score decreased steadily over the 12-week treatment period in both groups, with nearly identical trajectories observed for azithromycin and doxycycline recipients (Fig. 1). Table 2 Distribution of acne severity grades before intervention and after 12 weeks of treatment in the azithromycin and doxycycline groups (N = 163). Clear Mild Moderate Severe Very severe P-Value Before intervention 0.911 Azithromycin group 0 0 68 (81.9%) 14 (16.9%) 1 ((1.2%) Doxycycline group 0 0 64 (80.0%) 16 (20.0%) 0 After 3 months 0.704 Azithromycin group 57 (68.7%) 19(22.9%) 7 (8.4%) 0 0 Doxycycline group 59(73.8%) 16 (20.0%) 3 (3.8%) 1(1.2%) 1 (1.2%) Table 3 Pre- and post-treatment Acne-Specific Quality of Life (Acne-QoL) domain scores in azithromycin versus doxycycline recipients. subscale-level for the Acne-QoL Group Before After P Value Self-perception A 3.41 ± 1.55 4.56 ± 1.06 < 0.001* D 3.51 ± 1.1 4.68 ± 1.12 < 0.001* Role emotional A 2.97 ± 1.27 4.31 ± 1.15 < 0.001* D 3.11 ± 1.14 4.45 ± 1.03 < 0.001* Role Social A 3.76 ± 1.32 4.89 ± 1.03 < 0.001* D 3.93 ± 1.34 5.07 ± 1.06 < 0.001* Acne Symptoms A 3.31 ± 1.14 4.49 ± 0.9 < 0.001* D 3.26 ± 0.95 4.59 ± 0.9 < 0.001* A = azithromycin group; D = doxycycline group Quality-of-life scores improved significantly across all Acne-QoL domains in both groups. In the azithromycin group, self-perception scores rose from 3.41 ± 1.55 to 4.56 ± 1.06 ( P < 0.001), while in the doxycycline group they increased from 3.51 ± 1.10 to 4.68 ± 1.12 ( P < 0.001). Role-emotional scores improved from 2.97 ± 1.27 to 5.07 ± 1.06 ( P < 0.001); and symptom domain from 3.31 ± 1.14 to 4.49 ± 0.90 and from 3.26 ± 0.95 to 4.59 ± 0.90 ( P < 0.001). No significant intergroup differences were observed in any QoL domain post-treatment. Out of the total patients one patient from doxycycline group reported epigastric pain and 2 patients from azithromycin group reported diarrhoea and nausea, all of them completed the treatment. Regarding dropouts, two patients (2.5%) from doxycycline group stopped treatment because of lack of adherence while all patients in azithromycin group completed the treatment. Discussion This randomized controlled trial demonstrated comparable clinical efficacy between oral azithromycin and doxycycline in reducing acne lesions among young adults with moderate acne vulgaris after 12 weeks. The absence of statistically significant differences in treatment outcomes between these antibiotics aligns with prior literature. A meta-analysis of multiple randomized trials similarly concluded no discernible superiority between azithromycin and doxycycline, reinforcing their clinical interchangeability in treating inflammatory acne. 15 , 16 Both antibiotics effectively reduce the growth and inflammatory activity of Cutibacterium acnes , highlighting their similar therapeutic profiles. 5 , 15 – 17 Pharmacological differences between these agents may influence clinician choice, despite similar efficacy outcomes. Doxycycline, a tetracycline-class antibiotic, requires consistent daily administration, and is commonly associated with gastrointestinal disturbances and photosensitivity, potentially influencing patient adherence and comfort. 18 , 19 In contrast, azithromycin, a macrolide antibiotic, exhibits a longer tissue half-life allowing less frequent dosing. 20 , 21 The current study’s high adherence rates in both groups underscore both regimens' acceptability; however, azithromycin’s intermittent dosing potentially offers superior patient convenience and compliance, particularly relevant for students or young adults managing complex schedules. 22 Literature consistently highlights the adherence benefits of simplified dosing regimens, especially among adolescent and young adult populations who typically display variable adherence behaviors. 21 – 23 Importantly, the current trial reported minimal adverse events, aligning with other studies emphasizing favorable safety profiles for both azithromycin and doxycycline in acne therapy. 18 , 23 Nonetheless, doxycycline’s higher propensity for gastrointestinal side effects and photosensitivity reactions remains clinically relevant, particularly in geographical regions with significant sun exposure or in patients susceptible to these side effects. 18 , 19 Conversely, azithromycin’s comparatively mild adverse effect profile, absence of significant photosensitivity risks, and reduced pill burden may favor its selection in specific patient contexts, facilitating optimal antibiotic stewardship and patient satisfaction. In addition to clinical efficacy, this study demonstrated significant and parallel improvements in acne-related QoL across multiple domains—self-perception, role-social, role-emotional, and acne symptoms—highlighting the broad psychosocial impact of acne management. Prior research consistently documents the substantial psychological morbidity associated with acne, including diminished self-esteem, anxiety, and depression. 24 – 27 The current findings support evidence suggesting that effective acne treatment significantly alleviates these psychosocial burdens. For instance, studies by Kaikati et al. and Gallitano and Berson reported substantial QoL gains among acne patients upon clinical improvement, regardless of antibiotic regimen employed. 24 , 25 The use of a culturally validated Arabic Acne-QoL questionnaire strengthens the reliability and relevance of these findings, underscoring the real-world significance of clinical improvements in acne for patient psychological and emotional health. 28 The high adherence and minimal dropouts observed further affirm favorable patient acceptance and manageable treatment regimens in this trial. A retention rate approaching 100% is uncommon in acne trials, particularly within adolescent and young adult demographics, which typically show substantial dropout rates due to adherence issues or side effects. 29 Such high retention likely reflects effective patient counseling, manageable dosing regimens, and minimal adverse events observed in this study. Notably, the brief (12-week) treatment duration aligns with current dermatological guidelines advocating limited antibiotic use duration, contributing to adherence and minimizing resistance risks. 30 – 32 Antimicrobial resistance remains a critical global concern, mandating judicious antibiotic use in dermatology. Current acne treatment guidelines strongly advocate limiting systemic antibiotics to a maximum of three to four months, combined with topical agents such as benzoyl peroxide or retinoids, to mitigate antimicrobial resistance risks. 31 – 34 Nevertheless, evidence suggests that prolonged antibiotic treatments exceeding recommended durations remain widespread, exacerbating resistance concerns. 20 , 34 The current trial underscores that a short, guideline-concordant antibiotic regimen can achieve clinically meaningful results without extended exposure, emphasizing the feasibility and effectiveness of stewardship-compliant prescribing practices. Clinically, the current findings advocate flexibility in antibiotic selection, enabling clinicians to personalize acne therapy based on patient-specific factors, such as adherence potential, side effect susceptibility, and lifestyle considerations. While doxycycline remains a traditionally preferred oral antibiotic for acne, azithromycin presents a valuable alternative, especially when considering its pharmacological benefits, favorable tolerability, and convenient dosing schedule. Furthermore, azithromycin’s demonstrated safety during pregnancy and lactation represents a critical therapeutic advantage over doxycycline, contraindicated in these scenarios due to teratogenic risks and potential impacts on fetal bone and dental development. 35 – 37 Although the current study did not include pregnant or lactating patients, the broader implications of these safety considerations underscore azithromycin’s utility, particularly among reproductive-age female patients. The findings also highlight the critical importance of addressing acne’s psychosocial dimensions during treatment planning. Acne’s profound impact on patient quality of life is well-documented, with patients frequently experiencing feelings of embarrassment, anxiety, and social withdrawal. 24 – 26 Clinicians should therefore consider both dermatological and psychological outcomes when selecting acne therapies. The substantial QoL improvements observed reinforce the comprehensive benefit of achieving adequate acne clearance, promoting both dermatological and psychological well-being. This study’s primary strengths include its randomized controlled design, use of validated and culturally appropriate QoL measurement tools, excellent adherence, and comprehensive assessment of both clinical and patient-reported outcomes. These elements significantly enhance internal validity, providing robust, reliable evidence supporting azithromycin and doxycycline’s comparable efficacy and tolerability in moderate acne. However, several limitations warrant consideration. First, the open-label design inherently introduces expectation and observer bias risks, particularly relevant for subjective QoL outcomes. A double-blind approach would better control such biases, though differing dosing schedules of the medications presented practical challenges to blinding. Second, the single-center design and focused young adult population potentially limit external validity and generalizability. Broader multicenter studies involving diverse demographics could further validate the findings across varied clinical settings and populations. Third, the slight shortfall in participant enrollment (163 out of a planned 170 participants) marginally impacts statistical power, though the negligible difference observed between groups reduces the clinical relevance of this limitation. Lastly, the absence of longer-term follow-up precludes evaluating sustained treatment efficacy, durability of remission, and possible differences in relapse rates between the two antibiotics. Conclusion This randomized controlled trial substantiates oral azithromycin and doxycycline’s comparable clinical efficacy and significant QoL improvements in treating moderate acne vulgaris in young adults. Both antibiotics represent effective therapeutic options, with clinical decisions guided by patient-specific considerations, pharmacological properties, and stewardship guidelines. Adhering to short-duration antibiotic regimens, incorporating topical therapies, and closely monitoring psychosocial impacts ensure comprehensive, responsible, and effective acne management. Declarations Data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Competing interests The authors declare no competing interests. Funding No funding was received for this study. References Sutaria, A. H., Masood, S., Saleh, H., Schlessinger, J. & Acne Vulgaris [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459173/ Heng, A. H. S. & Chew, F. T. Systematic review of the epidemiology of acne vulgaris. Sci. Rep. 10 (1), 5754. 10.1038/s41598-020-62715-3 (2020). Published 2020 Apr 1. Fox, L., Csongradi, C., Aucamp, M., du Plessis, J. & Gerber, M. Treatment modalities for acne. Molecules 21 (8), 1063. 10.3390/molecules21081063 (2016). PMID: 27529209; PMCID: PMC6273829. Del Rosso, J. Q. Oral doxycycline in the management of acne vulgaris: current perspectives on clinical use and recent findings with a new double-scored small tablet formulation. J. Clin. Aesthet. Dermatol. 8 (5), 19–26 (2015). PMID: 26029331; PMCID: PMC4445892. Kus, S., Yucelten, D. & Aytug, A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin. Exp. Dermatol. 30 (3), 215–220. https://doi.org/10.1111/j.1365-2230.2005.01769.x (2005). Ullah, G., Noor, S. M., Bhatti, Z., Ahmad, M. & Bangash, A. R. Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris. J. Ayub Med. Coll. Abbottabad . 26 (1), 64–67 (2014 Jan-Mar). PMID: 25358221. Hanna, S., Sharma, J. & Klotz, J. Acne vulgaris - more than skin deep. Dermatol. Online J. 9 (3). https://doi.org/10.5070/D30t2870v9 (2003). Morshed, A. S. M. et al. Understanding the impact of acne vulgaris and associated psychological distress on self-esteem and quality of life via regression modelling with CADI, DLQI, and WHOQoL. Sci. Rep. 13 (1), 21084. 10.1038/s41598-023-48182-6 (2023). PMID: 38030667; PMCID: PMC10687248. Gupta, A., Sharma, Y. K., Dash, K. N., Chaudhari, N. D. & Jethani Quality of life in acne vulgaris: Relationship to clinical severity and demographic data. Indian J. Dermatol. Venereol. Leprol. 82 , 292–297. https://doi.org/10.4103/0378-6323.173593 (2016). Vilar, G. N., Santos, L. A. & Sobral Filho, J. F. Quality of life, self-esteem and psychosocial factors in adolescents with acne vulgaris. Bras. Dermatol. 90 (5), 622–629. 10.1590/abd1806-4841.201533726 (2015 Sep-Oct). PMID: 26560206; PMCID: PMC4631226. Chandani, K. U., Raval, R. C., Rana, D. A. & Malhotra, S. D. Study of drug use pattern & analysis of quality of life in patients of acne attending the dermatology opd in a tertiary care hospital: study of drug use pattern & analysis of quality of life in patients of acne attending the dermatology opd. Natl. J. Integr. Res. Med. 9 (1), 108–116. https://doi.org/10.70284/njirm.v9i1.1864 (2018). Ibrahim, N. K. et al. Acne vulgaris: prevalence, predictors, and factors influencing quality of life of female medical students at king abdulaziz university, jeddah. J. Dermatol. Dermatol. Surg. 23 (1), 7. https://doi.org/10.4103/jdds.jdds_39_18 (2019). Al-Shidhani, A., Al-Rashdi, S., Al-Habsi, H. & Rizvi, S. Impact of acne on quality of life of students at Sultan Qaboos university. Oman Med. J. 30 (1), 42–47. https://doi.org/10.5001/omj.2015.08 (2015). Acne-Specific Quality of Life Questionnaire (Acne-QoL). Manual and Interpretation Guide (Merck and Co., Inc, 1997). Kim, J. E. et al. Comparison of the efficacy of azithromycin versus doxycycline in acne vulgaris: a meta-analysis of randomized controlled trials. Ann. Dermatol. 30 (4), 417–426. 10.5021/ad.2018.30.4.417 (2018). Epub 2018 Jun 28. PMID: 30065581; PMCID: PMC6029975. Bienenfeld, A., Nagler, A. R. & Orlow, S. J. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am. J. Clin. Dermatol. 18 (4), 469–490. 10.1007/s40257-017-0267-z (2017). Baldwin, H. E. Oral antibiotic treatment options for acne vulgaris. J. Clin. Aesthet. Dermatol. 13 (9), 26–32 (2020). PMID:33133338. Thiboutot, D. M. et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J. Am. Acad. Dermatol. 78 (2 Suppl 1). 10.1016/j.jaad.2017.09.078 (2018). Epub 2017 Nov 8. PMID: 29127053S1-S23.e1. Zaenglein, A. L. et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 74 (5), 945–73e33. 10.1016/j.jaad.2015.12.037 (2016). Barbieri, J. S., Hoffstad, O. & Margolis, D. J. Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study. J. Am. Acad. Dermatol . 75 (6), 1142–1150e1. 10.1016/j.jaad.2016.06.057 (2016). Chernyshov, P. V. et al. Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J. Eur. Acad. Dermatol. Venereol. 32 (2), 194–208. 10.1111/jdv.14585 (2018). Dreno, B., Bettoli, V., Araviiskaia, E., Sanchez Viera, M. & Bouloc, A. The influence of exposome on acne. J. Eur. Acad. Dermatol. Venereol. 32 (5), 812–819. 10.1111/jdv.14820 (2018). Xu, S. et al. The analysis of acne increasing suicide risk. Med. (Baltim). 100 (24), e26035. 10.1097/MD.0000000000026035 (2021). PMID: 34128844; PMCID: PMC8213250. Halvorsen, J. A. et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. J. Invest. Dermatol. 131 (2), 363–370. 10.1038/jid.2010.264 (2011). Kaikati, J. et al. The impact of acne treatment on quality of life and self-esteem: a prospective cohort study from Lebanon. Int. J. Womens Dermatol. 7 (4), 415–421. 10.1016/j.ijwd.2021.03.005 (2021). Gallitano, S. M. & Berson, D. S. How acne bumps cause the blues: the influence of acne vulgaris on self-esteem. Int. J. Womens Dermatol. 4 (1), 12–17. 10.1016/j.ijwd.2017.10.004 (2018). Ogedegbe, E. E. & Henshaw, E. B. Severity and impact of acne vulgaris on the quality of life of adolescents in Nigeria. Clin. Cosmet. Investig Dermatol. 7 , 329–334. 10.2147/CCID.S73302 (2014). Hosthota, A., Bondade, S. & Basavaraja, V. Impact of acne vulgaris on quality of life and self-esteem. Cutis 98 (2), 121–124 (2016). PMID: 27622255. Tan, J. K. et al. Evaluation of essential clinical components and features of current acne global grading scales. J. Am. Acad. Dermatol. 69 (5), 754–761. 10.1016/j.jaad.2013.04.022 (2013). Leyden, J. J., Del Rosso, J. Q. & Baum, E. W. The use of antibiotics in the treatment of acne vulgaris: a review of current guidelines and best practices. J. Clin. Aesthet. Dermatol. 7 (5), 24–34 (2014). PMID: 24847407. Adler, B. L., Kornmehl, H. & Armstrong, A. W. Antibiotic resistance in acne treatment. JAMA Dermatol. 153 (8), 810–811. 10.1001/jamadermatol.2017.1297 (2017). Walsh, T. R., Efthimiou, J. & Dréno, B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infect. Dis. 16 (3), e23–e33. 10.1016/S1473-3099(15)00527-7 (2016). Aslam, I., Fleischer, A. & Feldman, S. Emerging drugs for the treatment of acne. Expert Opin. Emerg. Drugs . 20 (1), 91–101. 10.1517/14728214.2015.990374 (2015). Lee, Y. H., Liu, G., Thiboutot, D. M., Leslie, D. L. & Kirby, J. S. A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. J. Am. Acad. Dermatol. 71 (1), 70–76. 10.1016/j.jaad.2014.01.891 (2014). Bookstaver, P. B. et al. A review of antibiotic use in pregnancy. Pharmacotherapy 35 (11), 1052–1062. 10.1002/phar.1649 (2015). McMullan, P. et al. Safety of dermatologic medications in pregnancy and lactation: An update - Part I: Pregnancy. J. Am. Acad. Dermatol. 91 (4), 619–648. 10.1016/j.jaad.2023.10.072 (2024). Chi, C. C. et al. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst. Rev. (10), CD007346. 10.1002/14651858.CD007346.pub3 (2015). Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 27 Apr, 2026 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Revision requested 29 Dec, 2025 Reviews received at journal 25 Dec, 2025 Reviews received at journal 30 Nov, 2025 Reviewers agreed at journal 30 Nov, 2025 Reviews received at journal 29 Nov, 2025 Reviewers agreed at journal 29 Nov, 2025 Reviewers agreed at journal 27 Nov, 2025 Reviews received at journal 25 Nov, 2025 Reviewers agreed at journal 25 Nov, 2025 Reviewers agreed at journal 24 Nov, 2025 Reviewers agreed at journal 24 Nov, 2025 Reviewers agreed at journal 24 Nov, 2025 Reviewers agreed at journal 23 Nov, 2025 Reviewers invited by journal 23 Nov, 2025 Editor assigned by journal 23 Nov, 2025 Editor invited by journal 20 Nov, 2025 Submission checks completed at journal 20 Nov, 2025 First submitted to journal 20 Nov, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8068584","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":574963151,"identity":"6f2a2985-034f-4b7e-a3e3-4645a6e07e47","order_by":0,"name":"Asma AL Shidhani","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAElEQVRIiWNgGAWjYPCCAzwMN4BUQsUBCPcB8VrOHGDgAXETiNDCANbC2AbRwoBPC3//6cQPDH/uyPDdbn724OG8O3L2YocfAm2xk9NtwK5F4kbuZgnGtmc8kneOmRskbntmzCOdZgDUkmxsdgCHNTd4N0gwNhzmMbiRYCaRuO1wYo90AkjLgcRtOLTInz+7+QfDH5CW9G8SiXNAWtI/4NVicCB3mwQDG0hLDtCWBpCWHPy2GN7I3WaR2HaYR/JGTplEwrHDxjy3cwoOJBjg9osc0GE3Pvw5bM93I32b5I+aw3Lss9M3f/hQYSeH0/sgkIDFwXiUj4JRMApGwSggCADchms2640cAgAAAABJRU5ErkJggg==","orcid":"","institution":"Sultan Qaboos University Hospital","correspondingAuthor":true,"prefix":"","firstName":"Asma","middleName":"AL","lastName":"Shidhani","suffix":""},{"id":574963152,"identity":"6e6bc10d-f88e-4693-b9ed-c598b08fd821","order_by":1,"name":"Youssef Elsawy Mohammed","email":"","orcid":"","institution":"Sultan Qaboos University","correspondingAuthor":false,"prefix":"","firstName":"Youssef","middleName":"Elsawy","lastName":"Mohammed","suffix":""},{"id":574963153,"identity":"bc96c791-b40a-4ea0-bc49-f7247642f362","order_by":2,"name":"Jumana Al Saraii","email":"","orcid":"","institution":"Sultan Qaboos University","correspondingAuthor":false,"prefix":"","firstName":"Jumana","middleName":"Al","lastName":"Saraii","suffix":""},{"id":574963154,"identity":"cae85587-491c-441b-9913-6a23d6a5041b","order_by":3,"name":"Asma AL Salmani","email":"","orcid":"","institution":"Sultan Qaboos University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Asma","middleName":"AL","lastName":"Salmani","suffix":""},{"id":574963155,"identity":"3b5d77f3-e707-4056-a1c7-ef25c170833e","order_by":4,"name":"Maisa AL kiyumi","email":"","orcid":"","institution":"Sultan Qaboos University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Maisa","middleName":"AL","lastName":"kiyumi","suffix":""},{"id":574963156,"identity":"862fc7e1-5d53-450d-96cd-ef17c2727386","order_by":5,"name":"Ibrahim Al-Zakwani","email":"","orcid":"","institution":"Sultan Qaboos University","correspondingAuthor":false,"prefix":"","firstName":"Ibrahim","middleName":"","lastName":"Al-Zakwani","suffix":""},{"id":574963157,"identity":"759f1567-dfa0-435e-97e0-a7ff1b530826","order_by":6,"name":"Zalikha AL Balushi","email":"","orcid":"","institution":"Ministry of Health","correspondingAuthor":false,"prefix":"","firstName":"Zalikha","middleName":"AL","lastName":"Balushi","suffix":""},{"id":574963158,"identity":"cf679ab0-0f66-4d6c-950b-ab008f1fdfa2","order_by":7,"name":"AbdulAziz AL Mahrezi1","email":"","orcid":"","institution":"Sultan Qaboos University","correspondingAuthor":false,"prefix":"","firstName":"AbdulAziz","middleName":"AL","lastName":"Mahrezi1","suffix":""}],"badges":[],"createdAt":"2025-11-09 11:08:05","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8068584/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8068584/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-026-50567-2","type":"published","date":"2026-04-27T15:57:54+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":100600155,"identity":"b6fc6bae-e0b4-495d-992c-4ecb2d4bbb60","added_by":"auto","created_at":"2026-01-19 14:46:42","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":51025,"visible":true,"origin":"","legend":"","description":"","filename":"Acnemanuscriptfinal2docx.docx","url":"https://assets-eu.researchsquare.com/files/rs-8068584/v1/3a1d3bc3cd1f229fa799aab6.docx"},{"id":100600612,"identity":"201ab6ef-8a3e-4998-a69d-609f5a8818a6","added_by":"auto","created_at":"2026-01-19 14:48:54","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":9104,"visible":true,"origin":"","legend":"","description":"","filename":"b09131c44e694e88b6dd8b2e5fcd85d0.json","url":"https://assets-eu.researchsquare.com/files/rs-8068584/v1/580e769421d7edeac10116af.json"},{"id":100600177,"identity":"e9a9a2c3-23ee-48b8-9d48-f2ecb0726c8c","added_by":"auto","created_at":"2026-01-19 14:46:51","extension":"docx","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":14251,"visible":true,"origin":"","legend":"","description":"","filename":"Figure1.docx","url":"https://assets-eu.researchsquare.com/files/rs-8068584/v1/a1020e755ef0073741049701.docx"},{"id":100600256,"identity":"d28df1cd-9da2-4e22-a36d-e44e51fa67ea","added_by":"auto","created_at":"2026-01-19 14:47:13","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":94277,"visible":true,"origin":"","legend":"","description":"","filename":"b09131c44e694e88b6dd8b2e5fcd85d01enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8068584/v1/036c99e7034648530673dd5b.xml"},{"id":100600209,"identity":"a77f52a5-f370-4a01-acec-feccfc002cf5","added_by":"auto","created_at":"2026-01-19 14:46:55","extension":"xml","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":91956,"visible":true,"origin":"","legend":"","description":"","filename":"b09131c44e694e88b6dd8b2e5fcd85d01structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8068584/v1/66e8d28e5b772176dbdbf624.xml"},{"id":100600401,"identity":"3dd027fd-25b1-4936-93d1-6aaa519d0a41","added_by":"auto","created_at":"2026-01-19 14:47:53","extension":"html","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":103573,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8068584/v1/78aaa92626d52c5966465099.html"},{"id":100600315,"identity":"2f0ba953-3949-44f9-bfcf-6dc3f0fd958b","added_by":"auto","created_at":"2026-01-19 14:47:24","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":33519,"visible":true,"origin":"","legend":"\u003cp\u003ePercentage reduction in acne lesion count over 12 weeks in the azithromycin and doxycycline treatment groups.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8068584/v1/e80d420bec99a46b014f5df0.png"},{"id":108437993,"identity":"6c2006f4-b098-480e-afbd-174387632e4d","added_by":"auto","created_at":"2026-05-04 16:05:24","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":328380,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8068584/v1/04c80eb3-d2d3-4543-a4d7-6a34af11885d.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Efficacy of Oral Azithromycin versus Oral Doxycycline in Treating Moderate Acne Vulgaris and Their Effects on Patients' Quality of Life","fulltext":[{"header":"Introduction","content":"\u003cp\u003eAcne vulgaris is an inflammatory disorder of the pilosebaceous unit, in which proliferation of \u003cem\u003eCutibacterium acnes\u003c/em\u003e is precipitated by increased androgen activity during adolescence.\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e Clinically, it manifests as a mixture of comedones, papules, pustules and nodules on the face, upper arms, trunk, and back, with global prevalence estimates among adolescents ranging from approximately 35% to over 90%.\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eWhen moderate to severe inflammatory lesions fail to response adequately to topical therapies, systemic antibiotics such as doxycycline and azithromycin are indicated.\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e Doxycycline, a tetracycline derivative, has long been considered first-line but is frequently associated with photosensitivity and gastrointestinal upset.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e In contrast, azithromycin, a macrolide, offers a more favorable side-effect profile and is deemed safe for use during pregnancy and lactation.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e Comparative studies have yielded mixed outcomes: some report superior lesion-count reductions with doxycycline, while others demonstrate equivalent efficacy for azithromycin.\u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e,\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAlthough often dismissed as a transient adolescent condition, acne vulgaris imposes a substantial psychosocial burden that extends well beyond cutaneous involvement.\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e Affected individuals frequently experience diminished quality of life, impaired self-esteem and increased symptoms of anxiety and depression.\u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e In adults, acne has also been linked to higher unemployment rates and, in severe cases, elevated risk of suicidal ideation.\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eMultiple investigations confirm that stigmatization and peer teasing further exacerbate psychosocial distress in acne patients.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e Epidemiological data consistently show greater impairment among females,\u003csup\u003e8\u003c/sup\u003e with one study at King Abdulaziz University Hospital in Jeddah identifying the role-social domain as most compromised among female students.\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e Research at Sultan Qaboos University in Oman similarly found the role-emotional domain to be the most affected across both genders.\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eEvaluating both clinical efficacy and psychosocial outcomes is essential for comprehensive acne management. This study thus compares oral doxycycline and azithromycin in moderate acne vulgaris, examining patterns of dropout and loss of follow-up, and assesses changes in health-related quality of life before and after treatment.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003eThis phase IV, open-label, randomised controlled trial was conducted at the Sultan Qaboos University hospital student clinic, Muscat, Oman, from July 2023 to March 2024. Based on power calculations to detect an absolute difference in response rates of 25\u0026ndash;50% with 90% power at an alpha of 0.05, a sample size of 170 patients (85 per arm) was required.\u003c/p\u003e \u003cp\u003eStudents aged 17\u0026ndash;25 years with newly diagnosed moderate acne vulgaris (per the Acne Severity Scale) were screened. Exclusion criteria included systemic antibiotic use within the preceding months, pregnancy, current topical anti-acne or systemic steroid therapy, oral contraceptive use, active liver disease, or known allergy to azithromycin or doxycycline. Eligibility was confirmed by detailed history and complete physical examination, and written informed consent was obtained.\u003c/p\u003e \u003cp\u003eParticipants were stratified by gender and randomised\u0026mdash;using a computer-generated sequence managed by an independent physician\u0026mdash;to one of two treatment arms. Patients in the azithromycin arm received 500 mg once weekly (on Fridays) for the following 12 weeks, while those in the doxycycline arm were administered 100 mg once daily after meals throughout the 12-week treatment period. Monthly follow-up visits with an independent assessor documented acne severity and adverse events. Lesion clearance was categorised by percentage reduction\u0026mdash;excellent (100%), good (80\u0026ndash;90%), moderate (50\u0026ndash;79%), mild (30\u0026ndash;49%), and no response (\u0026lt;\u0026thinsp;30%)\u0026mdash;and side effects reported using the hospital adverse drug reaction (ADR) form. The primary response to treatment was assessed by using the difference in acne severity scale before treatment and after 3 months of treatment.\u003c/p\u003e \u003cp\u003eAll participants completed the validated Arabic acne-specific quality of life questionnaire (Acne-QoL) before treatment initiation and at week 12, assessing four domains: self-perception, role-social, role-emotional, and acne symptoms.\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e A total of 18 questions were distributed between these four domains. Permission to use the Acne-QoL was also obtained.\u003c/p\u003e \u003cp\u003eEthical approval was granted by the Medical Research Ethics Committee of the College of Medicine \u0026amp; Health Sciences (MREC#1914; 2/6/2019) and the trial was registered with the Australia New Zealand Clinical Trial Registry (ACTRN12619000073101; 18/1/2019). Written informed consent was obtained from each participant and participants below 17 years a parental informed consent was taken. All methods were followed according to relevant guidelines and regulations.\u003c/p\u003e \u003c/p\u003e \u003cp\u003eData were analysed using the Statistical Package for the Social Science (SPSS), Version 23 software (IBM Corp, Armonk, New York, USA). Quantitative variables are presented as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation. Between-group differences were assessed by independent t-test. paired t-test. and one-way ANOVA as appropriate, with \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05 denoting statistical significance.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eA total of 163 participants were randomised, with 83 (50.9%) assigned to the azithromycin group and 80 (49.1%) to the doxycycline group. Overall, 68.7% (n\u0026thinsp;=\u0026thinsp;112) were female; the mean age was 19.75\u0026thinsp;\u0026plusmn;\u0026thinsp;1.73 years (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eAge and gender distribution of study participants by treatment group (N\u0026thinsp;=\u0026thinsp;163).\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCharacteristic\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAzithromycin Group\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDoxycycline Group\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-Value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAge (mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SD)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e19.95\u0026thinsp;\u0026plusmn;\u0026thinsp;1.710\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19.54\u0026thinsp;\u0026plusmn;\u0026thinsp;1.743\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.550\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"4\" nameend=\"c4\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003eGender\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e26%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.984\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e57%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e55%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"4\"\u003e\u003cem\u003eSD\u0026thinsp;=\u0026thinsp;standard deviation\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eBaseline acne severity was comparable between groups (68 versus 64 moderates, 14 versus 16 severe, and 1 versus 0 very severe in the azithromycin versus doxycycline groups; \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.911; Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e). After 12 weeks, both regimens produced marked improvement: in the azithromycin group, 35 participants achieved clear skin, 19 had mild and 7 had moderate residual lesions, with none remaining in severe or very severe categories; in the doxycycline group, 37 achieved clear skin, 16 mild and 3 moderate severity, with one patient each in the severe and very severe categories (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.704). The mean acne severity score decreased steadily over the 12-week treatment period in both groups, with nearly identical trajectories observed for azithromycin and doxycycline recipients (Fig.\u0026nbsp;1).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eDistribution of acne severity grades before intervention and after 12 weeks of treatment in the azithromycin and doxycycline groups (N\u0026thinsp;=\u0026thinsp;163).\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eClear\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMild\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eModerate\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSevere\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eVery severe\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eP-Value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eBefore intervention\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.911\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAzithromycin group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e68 (81.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e14 (16.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1 ((1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDoxycycline group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e64 (80.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e16 (20.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eAfter 3 months\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e0.704\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAzithromycin group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e57 (68.7%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19(22.9%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e7 (8.4%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eDoxycycline group\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e59(73.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16 (20.0%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3 (3.8%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1(1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1 (1.2%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePre- and post-treatment Acne-Specific Quality of Life (Acne-QoL) domain scores in azithromycin versus doxycycline recipients.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\"\u0026plusmn;\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003esubscale-level for the Acne-QoL\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGroup\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBefore\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eAfter\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eP Value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSelf-perception\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.41\u0026thinsp;\u0026plusmn;\u0026thinsp;1.55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e4.56\u0026thinsp;\u0026plusmn;\u0026thinsp;1.06\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.51\u0026thinsp;\u0026plusmn;\u0026thinsp;1.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e4.68\u0026thinsp;\u0026plusmn;\u0026thinsp;1.12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eRole emotional\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e2.97\u0026thinsp;\u0026plusmn;\u0026thinsp;1.27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e4.31\u0026thinsp;\u0026plusmn;\u0026thinsp;1.15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.11\u0026thinsp;\u0026plusmn;\u0026thinsp;1.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e4.45\u0026thinsp;\u0026plusmn;\u0026thinsp;1.03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eRole Social\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.76\u0026thinsp;\u0026plusmn;\u0026thinsp;1.32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e4.89\u0026thinsp;\u0026plusmn;\u0026thinsp;1.03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.93\u0026thinsp;\u0026plusmn;\u0026thinsp;1.34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e5.07\u0026thinsp;\u0026plusmn;\u0026thinsp;1.06\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAcne Symptoms\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.31\u0026thinsp;\u0026plusmn;\u0026thinsp;1.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e4.49\u0026thinsp;\u0026plusmn;\u0026thinsp;0.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eD\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c3\"\u003e \u003cp\u003e3.26\u0026thinsp;\u0026plusmn;\u0026thinsp;0.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\"\u0026plusmn;\" colname=\"c4\"\u003e \u003cp\u003e4.59\u0026thinsp;\u0026plusmn;\u0026thinsp;0.9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u0026lt;\u0026thinsp;0.001*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e\u003cem\u003eA\u0026thinsp;=\u0026thinsp;azithromycin group; D\u0026thinsp;=\u0026thinsp;doxycycline group\u003c/em\u003e\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eQuality-of-life scores improved significantly across all Acne-QoL domains in both groups. In the azithromycin group, self-perception scores rose from 3.41\u0026thinsp;\u0026plusmn;\u0026thinsp;1.55 to 4.56\u0026thinsp;\u0026plusmn;\u0026thinsp;1.06 (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001), while in the doxycycline group they increased from 3.51\u0026thinsp;\u0026plusmn;\u0026thinsp;1.10 to 4.68\u0026thinsp;\u0026plusmn;\u0026thinsp;1.12 (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Role-emotional scores improved from 2.97\u0026thinsp;\u0026plusmn;\u0026thinsp;1.27 to 5.07\u0026thinsp;\u0026plusmn;\u0026thinsp;1.06 (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001); and symptom domain from 3.31\u0026thinsp;\u0026plusmn;\u0026thinsp;1.14 to 4.49\u0026thinsp;\u0026plusmn;\u0026thinsp;0.90 and from 3.26\u0026thinsp;\u0026plusmn;\u0026thinsp;0.95 to 4.59\u0026thinsp;\u0026plusmn;\u0026thinsp;0.90 (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001). No significant intergroup differences were observed in any QoL domain post-treatment.\u003c/p\u003e \u003cp\u003eOut of the total patients one patient from doxycycline group reported epigastric pain and 2 patients from azithromycin group reported diarrhoea and nausea, all of them completed the treatment. Regarding dropouts, two patients (2.5%) from doxycycline group stopped treatment because of lack of adherence while all patients in azithromycin group completed the treatment.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis randomized controlled trial demonstrated comparable clinical efficacy between oral azithromycin and doxycycline in reducing acne lesions among young adults with moderate acne vulgaris after 12 weeks. The absence of statistically significant differences in treatment outcomes between these antibiotics aligns with prior literature. A meta-analysis of multiple randomized trials similarly concluded no discernible superiority between azithromycin and doxycycline, reinforcing their clinical interchangeability in treating inflammatory acne.\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e Both antibiotics effectively reduce the growth and inflammatory activity of \u003cem\u003eCutibacterium acnes\u003c/em\u003e, highlighting their similar therapeutic profiles.\u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e,\u003cspan additionalcitationids=\"CR16\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003ePharmacological differences between these agents may influence clinician choice, despite similar efficacy outcomes. Doxycycline, a tetracycline-class antibiotic, requires consistent daily administration, and is commonly associated with gastrointestinal disturbances and photosensitivity, potentially influencing patient adherence and comfort.\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e In contrast, azithromycin, a macrolide antibiotic, exhibits a longer tissue half-life allowing less frequent dosing.\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e The current study\u0026rsquo;s high adherence rates in both groups underscore both regimens' acceptability; however, azithromycin\u0026rsquo;s intermittent dosing potentially offers superior patient convenience and compliance, particularly relevant for students or young adults managing complex schedules.\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e Literature consistently highlights the adherence benefits of simplified dosing regimens, especially among adolescent and young adult populations who typically display variable adherence behaviors.\u003csup\u003e\u003cspan additionalcitationids=\"CR22\" citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eImportantly, the current trial reported minimal adverse events, aligning with other studies emphasizing favorable safety profiles for both azithromycin and doxycycline in acne therapy.\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e Nonetheless, doxycycline\u0026rsquo;s higher propensity for gastrointestinal side effects and photosensitivity reactions remains clinically relevant, particularly in geographical regions with significant sun exposure or in patients susceptible to these side effects.\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e Conversely, azithromycin\u0026rsquo;s comparatively mild adverse effect profile, absence of significant photosensitivity risks, and reduced pill burden may favor its selection in specific patient contexts, facilitating optimal antibiotic stewardship and patient satisfaction.\u003c/p\u003e \u003cp\u003eIn addition to clinical efficacy, this study demonstrated significant and parallel improvements in acne-related QoL across multiple domains\u0026mdash;self-perception, role-social, role-emotional, and acne symptoms\u0026mdash;highlighting the broad psychosocial impact of acne management. Prior research consistently documents the substantial psychological morbidity associated with acne, including diminished self-esteem, anxiety, and depression.\u003csup\u003e\u003cspan additionalcitationids=\"CR25 CR26\" citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e The current findings support evidence suggesting that effective acne treatment significantly alleviates these psychosocial burdens. For instance, studies by Kaikati \u003cem\u003eet al.\u003c/em\u003e and Gallitano and Berson reported substantial QoL gains among acne patients upon clinical improvement, regardless of antibiotic regimen employed.\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e The use of a culturally validated Arabic Acne-QoL questionnaire strengthens the reliability and relevance of these findings, underscoring the real-world significance of clinical improvements in acne for patient psychological and emotional health.\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eThe high adherence and minimal dropouts observed further affirm favorable patient acceptance and manageable treatment regimens in this trial. A retention rate approaching 100% is uncommon in acne trials, particularly within adolescent and young adult demographics, which typically show substantial dropout rates due to adherence issues or side effects.\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e Such high retention likely reflects effective patient counseling, manageable dosing regimens, and minimal adverse events observed in this study. Notably, the brief (12-week) treatment duration aligns with current dermatological guidelines advocating limited antibiotic use duration, contributing to adherence and minimizing resistance risks.\u003csup\u003e\u003cspan additionalcitationids=\"CR31\" citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAntimicrobial resistance remains a critical global concern, mandating judicious antibiotic use in dermatology. Current acne treatment guidelines strongly advocate limiting systemic antibiotics to a maximum of three to four months, combined with topical agents such as benzoyl peroxide or retinoids, to mitigate antimicrobial resistance risks.\u003csup\u003e\u003cspan additionalcitationids=\"CR32 CR33\" citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e Nevertheless, evidence suggests that prolonged antibiotic treatments exceeding recommended durations remain widespread, exacerbating resistance concerns.\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e The current trial underscores that a short, guideline-concordant antibiotic regimen can achieve clinically meaningful results without extended exposure, emphasizing the feasibility and effectiveness of stewardship-compliant prescribing practices.\u003c/p\u003e \u003cp\u003eClinically, the current findings advocate flexibility in antibiotic selection, enabling clinicians to personalize acne therapy based on patient-specific factors, such as adherence potential, side effect susceptibility, and lifestyle considerations. While doxycycline remains a traditionally preferred oral antibiotic for acne, azithromycin presents a valuable alternative, especially when considering its pharmacological benefits, favorable tolerability, and convenient dosing schedule. Furthermore, azithromycin\u0026rsquo;s demonstrated safety during pregnancy and lactation represents a critical therapeutic advantage over doxycycline, contraindicated in these scenarios due to teratogenic risks and potential impacts on fetal bone and dental development.\u003csup\u003e\u003cspan additionalcitationids=\"CR36\" citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003eAlthough the current study did not include pregnant or lactating patients, the broader implications of these safety considerations underscore azithromycin\u0026rsquo;s utility, particularly among reproductive-age female patients.\u003c/p\u003e \u003cp\u003eThe findings also highlight the critical importance of addressing acne\u0026rsquo;s psychosocial dimensions during treatment planning. Acne\u0026rsquo;s profound impact on patient quality of life is well-documented, with patients frequently experiencing feelings of embarrassment, anxiety, and social withdrawal.\u003csup\u003e\u003cspan additionalcitationids=\"CR25\" citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e Clinicians should therefore consider both dermatological and psychological outcomes when selecting acne therapies. The substantial QoL improvements observed reinforce the comprehensive benefit of achieving adequate acne clearance, promoting both dermatological and psychological well-being.\u003c/p\u003e \u003cp\u003eThis study\u0026rsquo;s primary strengths include its randomized controlled design, use of validated and culturally appropriate QoL measurement tools, excellent adherence, and comprehensive assessment of both clinical and patient-reported outcomes. These elements significantly enhance internal validity, providing robust, reliable evidence supporting azithromycin and doxycycline\u0026rsquo;s comparable efficacy and tolerability in moderate acne.\u003c/p\u003e \u003cp\u003eHowever, several limitations warrant consideration. First, the open-label design inherently introduces expectation and observer bias risks, particularly relevant for subjective QoL outcomes. A double-blind approach would better control such biases, though differing dosing schedules of the medications presented practical challenges to blinding. Second, the single-center design and focused young adult population potentially limit external validity and generalizability. Broader multicenter studies involving diverse demographics could further validate the findings across varied clinical settings and populations. Third, the slight shortfall in participant enrollment (163 out of a planned 170 participants) marginally impacts statistical power, though the negligible difference observed between groups reduces the clinical relevance of this limitation. Lastly, the absence of longer-term follow-up precludes evaluating sustained treatment efficacy, durability of remission, and possible differences in relapse rates between the two antibiotics.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThis randomized controlled trial substantiates oral azithromycin and doxycycline\u0026rsquo;s comparable clinical efficacy and significant QoL improvements in treating moderate acne vulgaris in young adults. Both antibiotics represent effective therapeutic options, with clinical decisions guided by patient-specific considerations, pharmacological properties, and stewardship guidelines. Adhering to short-duration antibiotic regimens, incorporating topical therapies, and closely monitoring psychosocial impacts ensure comprehensive, responsible, and effective acne management.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo funding was received for this study.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eSutaria, A. H., Masood, S., Saleh, H., Schlessinger, J. \u0026amp; Acne Vulgaris [Updated 2023 Aug 17]. In: StatPearls [Internet]. \u003cem\u003eTreasure Island\u003c/em\u003e (FL): StatPearls Publishing; 2025 Jan-. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ncbi.nlm.nih.gov/books/NBK459173/\u003c/span\u003e\u003cspan address=\"https://www.ncbi.nlm.nih.gov/books/NBK459173/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeng, A. H. S. \u0026amp; Chew, F. T. Systematic review of the epidemiology of acne vulgaris. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e10\u003c/b\u003e (1), 5754. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-020-62715-3\u003c/span\u003e\u003cspan address=\"10.1038/s41598-020-62715-3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2020). Published 2020 Apr 1.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFox, L., Csongradi, C., Aucamp, M., du Plessis, J. \u0026amp; Gerber, M. Treatment modalities for acne. \u003cem\u003eMolecules\u003c/em\u003e \u003cb\u003e21\u003c/b\u003e (8), 1063. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/molecules21081063\u003c/span\u003e\u003cspan address=\"10.3390/molecules21081063\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016). PMID: 27529209; PMCID: PMC6273829.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDel Rosso, J. Q. Oral doxycycline in the management of acne vulgaris: current perspectives on clinical use and recent findings with a new double-scored small tablet formulation. \u003cem\u003eJ. Clin. Aesthet. Dermatol.\u003c/em\u003e \u003cb\u003e8\u003c/b\u003e (5), 19\u0026ndash;26 (2015). PMID: 26029331; PMCID: PMC4445892.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKus, S., Yucelten, D. \u0026amp; Aytug, A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. \u003cem\u003eClin. Exp. Dermatol.\u003c/em\u003e \u003cb\u003e30\u003c/b\u003e (3), 215\u0026ndash;220. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.1111/j.1365-2230.2005.01769.x\u003c/span\u003e\u003cspan address=\"10.1111/j.1365-2230.2005.01769.x\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2005).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUllah, G., Noor, S. M., Bhatti, Z., Ahmad, M. \u0026amp; Bangash, A. R. Comparison of oral azithromycin with oral doxycycline in the treatment of acne vulgaris. \u003cem\u003eJ. Ayub Med. Coll. Abbottabad\u003c/em\u003e. \u003cb\u003e26\u003c/b\u003e (1), 64\u0026ndash;67 (2014 Jan-Mar). PMID: 25358221.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHanna, S., Sharma, J. \u0026amp; Klotz, J. Acne vulgaris - more than skin deep. \u003cem\u003eDermatol. Online J.\u003c/em\u003e \u003cb\u003e9\u003c/b\u003e (3). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.5070/D30t2870v9\u003c/span\u003e\u003cspan address=\"10.5070/D30t2870v9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2003).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMorshed, A. S. M. et al. Understanding the impact of acne vulgaris and associated psychological distress on self-esteem and quality of life via regression modelling with CADI, DLQI, and WHOQoL. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e (1), 21084. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41598-023-48182-6\u003c/span\u003e\u003cspan address=\"10.1038/s41598-023-48182-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023). PMID: 38030667; PMCID: PMC10687248.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGupta, A., Sharma, Y. K., Dash, K. N., Chaudhari, N. D. \u0026amp; Jethani Quality of life in acne vulgaris: Relationship to clinical severity and demographic data. \u003cem\u003eIndian J. Dermatol. Venereol. Leprol.\u003c/em\u003e \u003cb\u003e82\u003c/b\u003e, 292\u0026ndash;297. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.4103/0378-6323.173593\u003c/span\u003e\u003cspan address=\"10.4103/0378-6323.173593\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVilar, G. N., Santos, L. A. \u0026amp; Sobral Filho, J. F. Quality of life, self-esteem and psychosocial factors in adolescents with acne vulgaris. \u003cem\u003eBras. Dermatol.\u003c/em\u003e \u003cb\u003e90\u003c/b\u003e (5), 622\u0026ndash;629. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1590/abd1806-4841.201533726\u003c/span\u003e\u003cspan address=\"10.1590/abd1806-4841.201533726\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015 Sep-Oct). PMID: 26560206; PMCID: PMC4631226.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChandani, K. U., Raval, R. C., Rana, D. A. \u0026amp; Malhotra, S. D. Study of drug use pattern \u0026amp; analysis of quality of life in patients of acne attending the dermatology opd in a tertiary care hospital: study of drug use pattern \u0026amp; analysis of quality of life in patients of acne attending the dermatology opd. \u003cem\u003eNatl. J. Integr. Res. Med.\u003c/em\u003e \u003cb\u003e9\u003c/b\u003e (1), 108\u0026ndash;116. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.70284/njirm.v9i1.1864\u003c/span\u003e\u003cspan address=\"10.70284/njirm.v9i1.1864\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIbrahim, N. K. et al. Acne vulgaris: prevalence, predictors, and factors influencing quality of life of female medical students at king abdulaziz university, jeddah. \u003cem\u003eJ. Dermatol. Dermatol. Surg.\u003c/em\u003e \u003cb\u003e23\u003c/b\u003e (1), 7. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.4103/jdds.jdds_39_18\u003c/span\u003e\u003cspan address=\"10.4103/jdds.jdds_39_18\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2019).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAl-Shidhani, A., Al-Rashdi, S., Al-Habsi, H. \u0026amp; Rizvi, S. Impact of acne on quality of life of students at Sultan Qaboos university. \u003cem\u003eOman Med. J.\u003c/em\u003e \u003cb\u003e30\u003c/b\u003e (1), 42\u0026ndash;47. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://doi.org/10.5001/omj.2015.08\u003c/span\u003e\u003cspan address=\"10.5001/omj.2015.08\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAcne-Specific Quality of Life Questionnaire (Acne-QoL). \u003cem\u003eManual and Interpretation Guide\u003c/em\u003e (Merck and Co., Inc, 1997).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKim, J. E. et al. Comparison of the efficacy of azithromycin versus doxycycline in acne vulgaris: a meta-analysis of randomized controlled trials. \u003cem\u003eAnn. Dermatol.\u003c/em\u003e \u003cb\u003e30\u003c/b\u003e (4), 417\u0026ndash;426. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.5021/ad.2018.30.4.417\u003c/span\u003e\u003cspan address=\"10.5021/ad.2018.30.4.417\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018). Epub 2018 Jun 28. PMID: 30065581; PMCID: PMC6029975.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBienenfeld, A., Nagler, A. R. \u0026amp; Orlow, S. J. Oral antibacterial therapy for acne vulgaris: an evidence-based review. \u003cem\u003eAm. J. Clin. Dermatol.\u003c/em\u003e \u003cb\u003e18\u003c/b\u003e (4), 469\u0026ndash;490. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s40257-017-0267-z\u003c/span\u003e\u003cspan address=\"10.1007/s40257-017-0267-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBaldwin, H. E. Oral antibiotic treatment options for acne vulgaris. \u003cem\u003eJ. Clin. Aesthet. Dermatol.\u003c/em\u003e \u003cb\u003e13\u003c/b\u003e (9), 26\u0026ndash;32 (2020). PMID:33133338.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThiboutot, D. M. et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. \u003cem\u003eJ. Am. Acad. Dermatol.\u003c/em\u003e \u003cb\u003e78\u003c/b\u003e (2 Suppl 1). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jaad.2017.09.078\u003c/span\u003e\u003cspan address=\"10.1016/j.jaad.2017.09.078\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018). Epub 2017 Nov 8. PMID: 29127053S1-S23.e1.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZaenglein, A. L. et al. Guidelines of care for the management of acne vulgaris. \u003cem\u003eJ. Am. Acad. Dermatol.\u003c/em\u003e \u003cb\u003e74\u003c/b\u003e (5), 945\u0026ndash;73e33. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jaad.2015.12.037\u003c/span\u003e\u003cspan address=\"10.1016/j.jaad.2015.12.037\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBarbieri, J. S., Hoffstad, O. \u0026amp; Margolis, D. J. Duration of oral tetracycline-class antibiotic therapy and use of topical retinoids for the treatment of acne among general practitioners (GP): A retrospective cohort study. \u003cem\u003eJ. Am. Acad. Dermatol\u003c/em\u003e. \u003cb\u003e75\u003c/b\u003e (6), 1142\u0026ndash;1150e1. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jaad.2016.06.057\u003c/span\u003e\u003cspan address=\"10.1016/j.jaad.2016.06.057\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChernyshov, P. V. et al. Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. \u003cem\u003eJ. Eur. Acad. Dermatol. Venereol.\u003c/em\u003e \u003cb\u003e32\u003c/b\u003e (2), 194\u0026ndash;208. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/jdv.14585\u003c/span\u003e\u003cspan address=\"10.1111/jdv.14585\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDreno, B., Bettoli, V., Araviiskaia, E., Sanchez Viera, M. \u0026amp; Bouloc, A. The influence of exposome on acne. \u003cem\u003eJ. Eur. Acad. Dermatol. Venereol.\u003c/em\u003e \u003cb\u003e32\u003c/b\u003e (5), 812\u0026ndash;819. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/jdv.14820\u003c/span\u003e\u003cspan address=\"10.1111/jdv.14820\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu, S. et al. The analysis of acne increasing suicide risk. \u003cem\u003eMed. (Baltim).\u003c/em\u003e \u003cb\u003e100\u003c/b\u003e (24), e26035. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/MD.0000000000026035\u003c/span\u003e\u003cspan address=\"10.1097/MD.0000000000026035\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021). PMID: 34128844; PMCID: PMC8213250.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHalvorsen, J. A. et al. Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population-based study. \u003cem\u003eJ. Invest. Dermatol.\u003c/em\u003e \u003cb\u003e131\u003c/b\u003e (2), 363\u0026ndash;370. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/jid.2010.264\u003c/span\u003e\u003cspan address=\"10.1038/jid.2010.264\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2011).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKaikati, J. et al. The impact of acne treatment on quality of life and self-esteem: a prospective cohort study from Lebanon. \u003cem\u003eInt. J. Womens Dermatol.\u003c/em\u003e \u003cb\u003e7\u003c/b\u003e (4), 415\u0026ndash;421. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ijwd.2021.03.005\u003c/span\u003e\u003cspan address=\"10.1016/j.ijwd.2021.03.005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2021).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGallitano, S. M. \u0026amp; Berson, D. S. How acne bumps cause the blues: the influence of acne vulgaris on self-esteem. \u003cem\u003eInt. J. Womens Dermatol.\u003c/em\u003e \u003cb\u003e4\u003c/b\u003e (1), 12\u0026ndash;17. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ijwd.2017.10.004\u003c/span\u003e\u003cspan address=\"10.1016/j.ijwd.2017.10.004\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2018).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOgedegbe, E. E. \u0026amp; Henshaw, E. B. Severity and impact of acne vulgaris on the quality of life of adolescents in Nigeria. \u003cem\u003eClin. Cosmet. Investig Dermatol.\u003c/em\u003e \u003cb\u003e7\u003c/b\u003e, 329\u0026ndash;334. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2147/CCID.S73302\u003c/span\u003e\u003cspan address=\"10.2147/CCID.S73302\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHosthota, A., Bondade, S. \u0026amp; Basavaraja, V. Impact of acne vulgaris on quality of life and self-esteem. \u003cem\u003eCutis\u003c/em\u003e \u003cb\u003e98\u003c/b\u003e (2), 121\u0026ndash;124 (2016). PMID: 27622255.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTan, J. K. et al. Evaluation of essential clinical components and features of current acne global grading scales. \u003cem\u003eJ. Am. Acad. Dermatol.\u003c/em\u003e \u003cb\u003e69\u003c/b\u003e (5), 754\u0026ndash;761. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jaad.2013.04.022\u003c/span\u003e\u003cspan address=\"10.1016/j.jaad.2013.04.022\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2013).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLeyden, J. J., Del Rosso, J. Q. \u0026amp; Baum, E. W. The use of antibiotics in the treatment of acne vulgaris: a review of current guidelines and best practices. \u003cem\u003eJ. Clin. Aesthet. Dermatol.\u003c/em\u003e \u003cb\u003e7\u003c/b\u003e (5), 24\u0026ndash;34 (2014). PMID: 24847407.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdler, B. L., Kornmehl, H. \u0026amp; Armstrong, A. W. Antibiotic resistance in acne treatment. \u003cem\u003eJAMA Dermatol.\u003c/em\u003e \u003cb\u003e153\u003c/b\u003e (8), 810\u0026ndash;811. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jamadermatol.2017.1297\u003c/span\u003e\u003cspan address=\"10.1001/jamadermatol.2017.1297\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2017).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWalsh, T. R., Efthimiou, J. \u0026amp; Dr\u0026eacute;no, B. Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. \u003cem\u003eLancet Infect. Dis.\u003c/em\u003e \u003cb\u003e16\u003c/b\u003e (3), e23\u0026ndash;e33. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S1473-3099(15)00527-7\u003c/span\u003e\u003cspan address=\"10.1016/S1473-3099(15)00527-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2016).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAslam, I., Fleischer, A. \u0026amp; Feldman, S. Emerging drugs for the treatment of acne. \u003cem\u003eExpert Opin. Emerg. Drugs\u003c/em\u003e. \u003cb\u003e20\u003c/b\u003e (1), 91\u0026ndash;101. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1517/14728214.2015.990374\u003c/span\u003e\u003cspan address=\"10.1517/14728214.2015.990374\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLee, Y. H., Liu, G., Thiboutot, D. M., Leslie, D. L. \u0026amp; Kirby, J. S. A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. \u003cem\u003eJ. Am. Acad. Dermatol.\u003c/em\u003e \u003cb\u003e71\u003c/b\u003e (1), 70\u0026ndash;76. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jaad.2014.01.891\u003c/span\u003e\u003cspan address=\"10.1016/j.jaad.2014.01.891\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2014).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBookstaver, P. B. et al. A review of antibiotic use in pregnancy. \u003cem\u003ePharmacotherapy\u003c/em\u003e \u003cb\u003e35\u003c/b\u003e (11), 1052\u0026ndash;1062. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/phar.1649\u003c/span\u003e\u003cspan address=\"10.1002/phar.1649\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcMullan, P. et al. Safety of dermatologic medications in pregnancy and lactation: An update - Part I: Pregnancy. \u003cem\u003eJ. Am. Acad. Dermatol.\u003c/em\u003e \u003cb\u003e91\u003c/b\u003e (4), 619\u0026ndash;648. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jaad.2023.10.072\u003c/span\u003e\u003cspan address=\"10.1016/j.jaad.2023.10.072\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2024).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChi, C. C. et al. Safety of topical corticosteroids in pregnancy. \u003cem\u003eCochrane Database Syst. Rev.\u003c/em\u003e (10), CD007346. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/14651858.CD007346.pub3\u003c/span\u003e\u003cspan address=\"10.1002/14651858.CD007346.pub3\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2015).\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Acne Vulgaris, doxycycline, Azithromycin, Oman, QoL","lastPublishedDoi":"10.21203/rs.3.rs-8068584/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8068584/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThis study aimed to compare the efficacy of oral azithromycin with oral doxycycline in moderate acne vulgaris and to assess the corresponding changes in patient-reported quality-of-life. In this open label, randomised controlled trial conducted at a university student clinic, Muscat, Oman, 163 patients with moderate and severe acne vulgaris were assigned equally to receive either oral azithromycin or oral doxycycline. Treatments were administered over a three-month period with monthly clinical assessments. Acne severity was quantified using a validated acne severity scale, and quality of life was measured at baseline and at study end via a standardised questionnaire. Analyses were performed using univariate statistics. The cohort comprised 163 participants (mean age 20.2\u0026thinsp;\u0026plusmn;\u0026thinsp;1.7 years; 67.3% female). Both groups experienced significant and comparable reductions in acne severity after three months. Parallel, statistically significant improvements were observed in quality-of-life scores across domains related to symptoms, emotional well-being, and social functioning. Oral azithromycin and doxycycline demonstrate equivalent efficacy in reducing moderate acne vulgaris and both confer substantial enhancements in patients\u0026rsquo; quality of life. These findings support either antibiotic as an appropriate option for addressing both the dermatological and psychosocial burdens of moderate acne. The trial was registered with the Australia New Zealand Clinical Trial Registry (ACTRN12619000073101; Date: 18th of January 2019).\u003c/p\u003e","manuscriptTitle":"Efficacy of Oral Azithromycin versus Oral Doxycycline in Treating Moderate Acne Vulgaris and Their Effects on Patients' Quality of Life","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-01-19 13:43:07","doi":"10.21203/rs.3.rs-8068584/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-12-29T11:17:00+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-12-26T00:11:57+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-11-30T20:16:56+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"132027808253506062656527604995724396844","date":"2025-11-30T19:39:55+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-11-29T13:36:30+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"318016435599413866624193005818644654889","date":"2025-11-29T13:21:14+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"154037376257205544020161922419975317505","date":"2025-11-27T10:43:09+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-11-26T00:39:02+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"163023277605005319741766802830313958816","date":"2025-11-26T00:03:43+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"19398823240616755151696147676990405474","date":"2025-11-24T08:06:57+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"150215649532575564222622085264107005225","date":"2025-11-24T07:35:16+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"7522775431303314540407328498024032837","date":"2025-11-24T07:03:05+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"276877264640786481292194063218208065224","date":"2025-11-23T07:53:33+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-11-23T06:06:38+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-11-23T06:02:09+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-11-20T19:28:23+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-11-20T08:01:51+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2025-11-20T07:58:41+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"31b3c917-d218-4f5c-ad9a-a9244b5e2ebc","owner":[],"postedDate":"January 19th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2026-05-04T16:05:13+00:00","versionOfRecord":{"articleIdentity":"rs-8068584","link":"https://doi.org/10.1038/s41598-026-50567-2","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2026-04-27 15:57:54","publishedOnDateReadable":"April 27th, 2026"},"versionCreatedAt":"2026-01-19 13:43:07","video":"","vorDoi":"10.1038/s41598-026-50567-2","vorDoiUrl":"https://doi.org/10.1038/s41598-026-50567-2","workflowStages":[]},"version":"v1","identity":"rs-8068584","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8068584","identity":"rs-8068584","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}